Gilead Sciences (GILD) Revenue — Quarter Ended Dec 31, 2025
Revenue for the quarter increased both sequentially and compared to the same period last year. This marks the fourth consecutive quarter of positive year-over-year growth, with the pace accelerating throughout the fiscal year.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue for the quarter increased both sequentially and compared to the same period last year. This marks the fourth consecutive quarter of positive year-over-year growth, with the pace accelerating throughout the fiscal year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$7.9B
Revenue reported for this quarter.
Quarter-over-quarter
+2.0%
Change from the immediately preceding quarter.
Year-over-year
+4.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$29.4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $6.7B | -0.3% |
| Jun 30, 2025 | $7.1B | +1.8% |
| Sep 30, 2025 | $7.8B | +3.0% |
| Dec 31, 2025 | $7.9B | +4.7% |
Revenue performance
Revenue rose in the current quarter, driven by gains from the prior quarter and a year earlier.
Quarterly comparison
Compared to the immediately preceding quarter, revenue increased. On a year-over-year basis, revenue also rose, extending the positive trend from earlier in the fiscal year.
What to watch
The accelerating pace of year-over-year revenue growth over the past four quarters may warrant attention for sustained performance.